


## Viral Epidemiology Snapshot: February 4-10, 2024


Prepared by Anne Hall, Ph.D., M(ASCP) on behalf of the Molecular Diagnostics/Virology Labs

CoV-2, Flu, & RSV					
<u>Virus</u>	#Tested	#Positive	% Positive		
Flu A	1406	247	17.6%		
Flu B	1406	354	25.2%		
RSV	382	35	9.2%		
CoV-2	898	76	8.5%		

Bacterial Respiratory Infections (Molecular Tests)					
<u>Organism</u>	#Tested	#Positive	% Positive		
Bordetella parapertussis	370	0	0.0%		
Bordetella pertussis	370	0	0.0%		
Chlamydia pneumoniae	368	0	0.0%		
Mycoplasma pneumoniae	368	0	0.0%		

Other Respiratory Viruses				
<u>Virus</u>	#Tested	#Positive	% Positive	
Adenovirus	368	18	4.9%	
Coronavirus 229E	368	6	1.6%	
Coronavirus HKU1	368	8	2.2%	
Coronavirus NL63	368	6	1.6%	
Coronavirus OC43	368	27	7.3%	
Metapneumovirus	368	4	1.1%	
Rhinovirus/Enterovirus	368	107	29.1%	
Parainfluenza 1	368	0	0.0%	
Parainfluenza 2	368	0	0.0%	
Parainfluenza 3	368	4	1.1%	
Parainfluenza 4	368	1	0.3%	





Flu A Subtyping				
2009 H1N1	38			
Seasonal H1	0			
Seasonal H3	8			
No Subtype	201			
Pending subtype	0			

This report contains results for all tests ordered throughout the CHMCA network. As of 9/19/23, the data set includes all Point of Care Testing performed at ACHPs and Urgent Care Centers, as well as the central hospital laboratories.

As of 10/1/23, SARS-CoV-2 will be tracked in total, rather than in "Diagnostic" and "Screening" categories

The top chart displays the 8-week trend for total number of positive tests for Flu A, Flu B, RSV, and SARS-CoV-2.

The bottom chart displays the 8-week trend for positivity rate (# positive/ total # tested) Flu A, Flu B, RSV, and SARS-CoV-2.

